Document:

EX-10.11

 Exhibit 10.11 

MODERNA, INC. 

AMENDED AND RESTATED EXECUTIVE SEVERANCE PLAN

 1. Purpose. Moderna, Inc. (the “Company”) considers it essential to the best interests of the Company to foster the
continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many corporations, the possibility of an involuntary termination of employment, either
before or after a Change in Control (as defined in Section 2 hereof), exists and that such possibility, and the uncertainty and questions that it may raise among management, may result in the departure or distraction of management
personnel to the detriment of the Company. Therefore, the Board has determined that the Moderna, Inc. Amended and Restated Executive Severance Plan (the “Plan”) should be adopted to reinforce and encourage the continued attention and
dedication of the Company’s Covered Executives (as defined in Section 2 hereof) to their assigned duties without distraction. Nothing in this Plan shall be construed as creating an express or implied contract of employment and nothing
shall alter the “at will” nature of the Covered Executives’ employment with the Company. 
 2. Definitions. The
following terms shall be defined as set forth below: 
 (a) “Accounting Firm” shall mean a nationally
recognized accounting firm selected by the Company. 
 (b) “Administrator” means the Board or the Compensation Committee of
the Board. 
 (c) “Cause” shall mean, and shall be limited to, the occurrence of any one or more of the following events:

 (i) the Covered Executive’s unauthorized use or disclosure of the Company’s confidential information or trade
secrets; 
 (ii) the Covered Executive’s material breach of any agreement between the Covered Executive and the Company;

 (iii) the Covered Executive’s material failure to comply with the Company’s written policies or rules; 

(iv) the Covered Executive’s gross negligence or willful misconduct in connection with the Executive’s performance of
his/her duties to the Company; 
 (v) the Covered Executive’s continuing failure to perform assigned duties after
receiving written notification of the failure from the Company and, if curable, a period of thirty (30) days to cure such failure; or 

(vi) the Covered Executive’s failure to cooperate in good faith with a governmental or internal investigation of the
Company or its directors, officers or employees, if the Company has requested the Covered Executive’s cooperation. 

 (d) “Change in Control” shall mean 

(i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity;

 (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting
power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable)
immediately upon completion of such transaction; 
 (iii) the sale of all of the outstanding stock of the Company to an
unrelated person, entity or group thereof acting in concert; or 
 (iv) any other transaction in which the owners of the
Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result
of the acquisition of securities directly from the Company. 
 (e) “Change in Control Period” shall mean the period
beginning on the date of a Change in Control and ending on the one-year anniversary of the Change in Control. 

(f) “Code” shall mean the Internal Revenue Code of 1986, as amended. 

(g) “Covered Executives” shall mean the individuals designated as such by the Administrator and who are listed in Exhibit
A, attached hereto, as such exhibit is amended by the Administrator from time to time. 
 (h) “Date of Termination”
shall mean the date that a Covered Executive’s employment with the Company (or any successor) ends, which date shall be specified in the Notice of Termination. Notwithstanding the foregoing, a Covered Executive’s employment shall not be
deemed to have been terminated solely as a result of the Covered Executive becoming an employee of any direct or indirect successor to the business or assets of the Company. 

(i) “Disability” shall mean the following: if through any illness, injury, accident or condition of either a physical or
psychological nature, the Covered Executive becomes unable to perform substantially all of his duties and responsibilities for a continuous period of sixteen (16) consecutive weeks or for any twenty-six
(26) weeks within a fifty-two (52) week period. Determinations as to whether Covered Executive is Disabled shall be made by a physician selected
by the Board or its insurers and acceptable to the Covered Executive or the Covered Executive’s legal representative, such agreement as to acceptability not to be unreasonably withheld or delayed. 

(j) “Good Reason” shall mean that the Covered Executive has complied with the “Good Reason Process” following the
occurrence of any of the following events: 

  
 2 

 (i) a material diminution in the Covered Executive’s annual base salary
other than across the board decreases in annual base salary similarly affecting all executives of the Company; 
 (ii) the
Company requiring the Covered Executive to relocate (other than for travel incident to the Covered Executive’s performance of his or her duties on behalf of the Company) a distance of more than fifty (50) miles from the Covered
Executive’s current principal place of business; or 
 (iii) any material diminution in the Covered Executive’s
position, responsibilities, authority or duties. 
 For purposes of Section 2(j)(iii), a change in the reporting relationship, or a change in a title
will not, by itself, be sufficient to constitute a material diminution of responsibilities, authority or duty. 
 (k) “Good Reason
Process” shall mean: 
 (i) the Covered Executive reasonably determines in good faith that a “Good Reason”
condition has occurred; 
 (ii) the Covered Executive notifies the Company in writing of the first occurrence of the Good
Reason condition within sixty (60) days of the first occurrence of such condition; 
 (iii) the Covered Executive
cooperates in good faith with the Company’s efforts, for a period of not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; 

(iv) notwithstanding such efforts, the Good Reason condition continues to exist following the Cure Period; and 

(v) the Covered Executive terminates his or her employment and provides the Company with a Notice of Termination with respect
to such termination, each within sixty (60) days after the end of the Cure Period. 
 If the Company cures the Good Reason condition
during the Cure Period, Good Reason shall be deemed not to have occurred. 
 (l) “Notice of Termination” shall mean a
written notice which shall indicate the specific termination provision in this Plan relied upon for the termination of a Covered Executive’s employment and the Date of Termination. 

(m) “Participation Agreement” shall mean an agreement between a Covered Executive and the Company that
acknowledges the Covered Executive’s participation in the Plan.  

  
 3 

 (n) “Qualified Termination Event” shall mean (i) a termination of the
Covered Executive’s employment by the Company other than for Cause, death or Disability or (ii) the Covered Executive’s resignation from the Company for Good Reason. 

(o) “Restrictive Covenants Agreement” shall mean the Employee Confidentiality,
Non-Competition, Non-Solicitation and Inventions Assignment Agreement or similar agreement entered into between the Covered Executive and the Company. 

3. Administration of the Plan.  

(a) Administrator. The Plan shall be administered by the Administrator. 

(b) Powers of Administrator. The Administrator shall have all powers necessary to enable it properly to carry out its duties with
respect to the complete control of the administration of the Plan. Not in limitation, but in amplification of the foregoing, the Administrator shall have the power and authority in its discretion to: 

(i) construe the Plan to determine all questions that shall arise as to interpretations of the Plan’s provisions; 

(ii) determine which individuals are and are not Covered Executives, determine the benefits to which any Covered Executives may
be entitled, the eligibility requirements for participation in the Plan and all other matters pertaining to the Plan; 

(iii) adopt amendments to the Plan which are deemed necessary or desirable to comply with all applicable laws and regulations,
including but not limited to Code Section 409A and the guidance thereunder; 
 (iv) make all determinations it deems
advisable for the administration of the Plan, including the authority and ability to delegate administrative functions to a third party; 

(v) decide all disputes arising in connection with the Plan; and 

(vi) otherwise supervise the administration of the Plan. 

(c) All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Covered Executives. 

4. Eligibility. All Covered Executives who have executed and submitted to the Company a Participation Agreement, and satisfied such
other requirements as may be determined by the Administrator, are eligible to participate in the Plan. 
 5. Termination Benefits
Generally. In the event a Covered Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Covered Executive any earned but unpaid salary, unpaid expense reimbursements in accordance with
Company policy, accrued but unused vacation, if any and any vested benefits the Covered Executive may have under any employee benefit plan of the Company in accordance with the terms and conditions of such employee benefit plan (collectively, the
“Accrued Benefits”), within the time required by law but in no event more than sixty (60) days after the Date of Termination. 

  
 4 

 6. Termination Not in Connection with a Change in Control. In the event a Qualified
Termination occurs at any time other than during the Change in Control Period, with respect to such Covered Executive, in addition to the Accrued Benefits, subject to his or her execution of a separation agreement in a form and manner satisfactory
to the Company containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property, non-disparagement and reaffirmation
of the Restrictive Covenants Agreement (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming irrevocable, all within the time period set forth in the Separation Agreement and Release but in no event
more than sixty (60) days after the Date of Termination, and subject to the Covered Executive complying with the Separation Agreement and Release, the Company shall: 

(a) pay the Covered Executive an amount equal to the sum of (i) twelve (12) months of the Covered Executive’s annual base salary in
effect immediately prior to the Qualified Termination Event plus (ii) an amount equal to the Covered Executive’s annual target bonus in effect immediately prior to the Qualified Termination Event multiplied by a fraction with a numerator
equal to the number of full weeks elapsed in the then current fiscal year prior to the Date of Termination and with a denominator equal to fifty-two (52); and 

(b) if the Covered Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects
COBRA health continuation, then the Company shall pay to the Covered Executive a monthly cash payment for twelve (12) months or the Covered Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Covered Executive if the Covered Executive had remained employed by the Company, based on the premiums as of the Date of Termination. 

The amounts payable under Section 6(a) and (b) shall be paid out in substantially equal installments in accordance with the Company’s payroll
practice over twelve (12) months commencing within sixty (60) days after the Date of Termination; provided, however, that if the 60-day period begins in one (1) calendar year and ends in
a second calendar year, the severance shall begin to be paid in the second calendar year by the last day of such 60-day period; provided further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Plan is intended to constitute a separate payment for purposes of Treasury
Regulation Section 1.409A-2(b)(2). 
 7. Termination in Connection with a Change in
Control. In the event the Qualified Termination Event occurs within the Change in Control Period, then with respect to such Covered Executive, in addition to the Accrued Benefits, subject to his or her execution and non-revocation of the Separation Agreement and Release, all within the time period set forth in the Separation Agreement and Release, but in no event more than sixty (60) days after the Date of Termination, the
Company shall: 

  
 5 

 (a) cause 100% of the outstanding and unvested equity awards with time-based vesting held by
the Covered Executive to immediately become fully exercisable or nonforfeitable as of the Date of Termination. Notwithstanding the foregoing, in the event of a Change in Control where the parties
to such Change in Control do not provide for the assumption, continuation or substitution of equity awards of the Company, any and all outstanding and unvested equity awards held by the Covered Executive shall be subject to Section 3(d) of the
Company’s 2018 Stock Option and Incentive Plan, if adopted by the Board. 
 (b) pay to the Covered Executive an amount equal to the sum
of (i) 150% of the Covered Executive’s annual base salary in effect immediately prior to the Qualified Termination Event (or the Covered Executive’s annual base salary in effect immediately prior to the Change in Control, if higher) plus
(ii) 150% of the Covered Executive’s annual target bonus in effect immediately prior to the Qualified Termination Event (or the Covered Executive’s target bonus in effect immediately prior to the Change in Control, if higher, (such higher
annual target bonus, the “Applicable Bonus”)) plus (iii) an amount equal to the Covered Executive’s Applicable Bonus multiplied by a fraction with a numerator equal to the number of full weeks elapsed in the then current fiscal
year prior to the Date of Termination and with a denominator equal to fifty-two (52); and 
 (c) if
the Covered Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Covered Executive a lump sum cash payment in an
amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Covered Executive if the Covered Executive had remained employed by the Company for eighteen (18) months after the Date of
Termination, based on the premiums as of the Date of Termination. 
 The amounts payable under Section 7(b) and (c), as applicable, shall be paid out
in a lump sum within sixty (60) days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the amounts shall be paid
in the second calendar year no later than the last day of the 60-day period. For the avoidance of doubt, the severance pay and benefits provided in this Section 7 shall apply in lieu of, and expressly
supersede, the provisions of Section 6 and no Covered Executive shall be entitled to the severance pay and benefits under both Section 6 and 7 hereof. 

8. Additional Limitation. 

(a) Anything in this Plan to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the
Company to or for the benefit of the Covered Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Plan or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable
regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate
Payments shall be $1.00 less than the amount at which the Covered Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Covered Executive
receiving a higher After Tax Amount (as defined below) than the Covered Executive 

  
 6 

 
would receive if the Aggregate Payments were not subject to such reduction. In the event of such reduction, the Aggregate Payments shall be reduced in the following order, in each case, in
reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A
of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the
foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced
before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c). 

(b) For purposes of this Section 8, the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state,
and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes
at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each
applicable state and locality, net of the maximum reduction in federal income taxes (if any) which could be obtained from deduction of such state and local taxes. 

(c) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 8(a) shall be made by the
Accounting Firm, which shall provide detailed supporting calculations both to the Company and the Covered Executive within fifteen (15) business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested
by the Company or the Covered Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Covered Executive. 

9. Employee Non-Competition, Non-Solicitation and
Confidentiality and Assignment Agreement. 
 (a) Employee Non-Competition, Non-Solicitation and Confidentiality and Assignment Agreement. As a condition to participating in the Plan, each Covered Executive shall continue to comply with the terms and conditions contained in the
Restrictive Covenants Agreements or similar agreement entered into between the Covered Executive and the Company and such other agreement(s) as designated in the applicable Participation Agreement. If a Covered Executive has not entered into a
Restrictive Covenants Agreement or similar agreement with the Company, he or she shall enter into such agreement prior to participating in the Plan.  

10. Withholding. All payments made by the Company under this Plan shall be subject to any tax or other amounts required to be withheld
by the Company under applicable law. 

  
 7 

 11. Section 409A. 

(a) Anything in this Plan to the contrary notwithstanding, if at the time of the Covered Executive’s “separation from service”
within the meaning of Section 409A of the Code, the Company determines that the Covered Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Covered Executive becomes entitled to under this Plan would be considered deferred compensation subject to the twenty (20) percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of
Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six (6) months and one (1) day after the Covered Executive’s separation from
service, or (ii) the Covered Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that
would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) The parties intend that this Plan will be administered in accordance with Section 409A of the Code and that all amounts payable
hereunder shall be exempt from the requirements of such section as a result of being “short term deferrals” for purposes of Section 409A of the Code to the greatest extent possible. To the extent that any provision of this Plan is not
exempt from Section 409A of the Code and ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner to comply with Section 409A of the Code. Each payment pursuant to this Plan is
intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Plan may be amended, as reasonably requested by either party, and as may
be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(c) To the extent that any payment or benefit described in this Plan constitutes “non-qualified
deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Covered Executive’s termination of employment, then such payments or benefits shall be payable only upon the
Covered Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 
 (d) All in-kind benefits provided and
expenses eligible for reimbursement under this Plan shall be provided by the Company or incurred by the Covered Executive during the time periods set forth in this Plan. All reimbursements shall be paid as soon as administratively practicable, but
in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses
incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(e) The Company makes no representation or warranty and shall have no liability to the Covered Executive or any other person if any provisions
of this Plan are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

  
 8 

 12. Notice and Date of Termination.  

(a) Notice of Termination. A termination of the Covered Executive’s employment shall be communicated by Notice of Termination from
the Company to the Covered Executive or vice versa in accordance with this Section 12. 
 (b) Notice to the Company. Any notices,
requests, demands, and other communications provided for by this Plan shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to a Covered Executive at the last address the Covered
Executive has filed in writing with the Company, or to the Company at the following physical or email address: 
 Moderna, Inc. 

Attention: Chief Human Resources Officer 

200 Technology Square 
 Cambridge,
MA 02139 
 Annie.drapeau@modernatx.com 

13. No Mitigation. The Covered Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable
to the Covered Executive by the Company under this Plan. 
 14. Benefits and Burdens. This Plan shall inure to the benefit of and be
binding upon the Company and the Covered Executives, their respective successors, executors, administrators, heirs and permitted assigns. In the event of a Covered Executive’s death after a termination of employment but prior to the completion
by the Company of all payments due to him or her under this Plan, the Company shall continue such payments to the Covered Executive’s beneficiary designated in writing to the Company prior to his or her death (or to his or her estate, if the
Covered Executive fails to make such designation). 
 15. Enforceability. If any portion or provision of this Plan shall to any extent
be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Plan, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Plan shall be valid and enforceable to the fullest extent permitted by law. 

16. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of
any party to require the performance of any term or obligation of this Plan, or the waiver by any party of any breach of this Plan, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent
breach. 
 17. Non-Duplication of Benefits and Effect on Other Plans. Notwithstanding any
other provision in the Plan to the contrary, the benefits provided hereunder shall be in lieu of any other severance payments and/or benefits provided by the Company, including any such payments and/or benefits pursuant to an employment agreement or
offer letter between the Company and the Covered Executive, other than as provided in Section 3(d) of the Company’s 2018 Stock Option and Incentive Plan, if adopted by the Board. 

  
 9 

 18. No Contract of Employment. Nothing in this Plan shall be construed as giving any
Covered Executive any right to be retained in the employ of the Company or shall affect the terms and conditions of a Covered Executive’s employment with the Company. 

19. Amendment or Termination of Plan. The Company may amend or terminate this Plan at any time or from time to time, but no such action
shall adversely affect the rights of any Covered Executive without the Covered Executive’s written consent. 
 20. Governing Law.
This Plan shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles. 

21. Obligations of Successors(c) . In addition to any obligations imposed by law upon any successor to the Company, any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company shall expressly assume and agree to perform this Plan in the same manner and to the same extent that
the Company would be required to perform if no such succession had taken place. 
 22. Effectiveness and Term. The Executive Severance
Plan is effective as of June 13, 2018 and was amended and restated as of November 4, 2018. 

  
 10 

 Exhibit A 

Covered Executives 

  
 11 

 [DATE] 

[NAME] 
 [ADDRESS] 

[ADDRESS] 
 Re: Amended and Restated Executive Severance Plan

 Dear [NAME], 
 Moderna, Inc. (the “Company”)
is pleased to inform you that you have been designated as an eligible participant in the Company’s Amended and Restated Executive Severance Plan, as amended from time to time (the “Severance Plan”), a copy of which (excluding the
exhibits thereto) is attached hereto as Exhibit A. You have been designated as a Covered Executive under the Severance Plan. 
 Under certain
circumstances, you will be eligible for certain severance benefits as described in the Severance Plan. Any and all such severance benefits are subject to the terms and conditions of the Severance Plan. 

As a condition to participate in the Severance Plan, you hereby acknowledge that the severance benefits that may be provided to you under the Severance Plan
will supersede and replace any severance benefit plan, policy or practice previously maintained by the Company or any of its affiliates that may have been applicable to you and any severance benefits under any individually negotiated employment
agreement, offer letter agreement or equity award agreement between you and the Company or any of its affiliates, as may be amended from time to time, including without limitation the [offer letter][equity award agreement] between you and Moderna,
Inc., dated [DATE], but other than Section 3(d) of the Company’s 2018 Stock Option and Incentive Plan, if adopted by the Company’s board of directors. In addition, as a condition to participate in the Severance Plan, you hereby
acknowledge that you will continue to comply with the Employee Confidentiality, Non-Competition, Non-Solicitation and Inventions Assignment Agreement entered into
between you and the Company on [DATE]. 
 Please review the information in this letter and the Severance Plan carefully. If you have any questions regarding
the letter or the Severance Plan, please contact Annie Drapeau at Annie.drapeau@modernatx.com. 
 To accept the terms of this letter and participate in the
Severance Plan, please sign and date this letter in the space provided below and return the signed copy to Annie Drapeau by [DATE] (the “Expiration Date”). If you do not return the signed copy by the Expiration Date, the terms of this
letter shall be null and void and you may not participate in the Severance Plan. 
  

	
	Moderna, Inc.
	
	  

	Name:
	Title:
	
	Agreed and Accepted:
	
	  

	Name:
	Date:

 Exhibit A 

Moderna, Inc. Amended and Restated Executive Severance PlanEX-10.12

 Exhibit 10.12 

ModeRNA Therapeutics, Inc. 
 February 23, 2011

 Stephane Bancel 
 Boston, MA 

Dear Stephane: 
 It is my pleasure to confirm our offer to you
for the position of Chief Executive Officer and Board Member for ModeRNA Therapeutics, Inc. (“Company”). 
 Compensation: You will receive
a base salary of $400,000 annually prorated for four-fifths (4/5) time, which will be paid semi-monthly during the term of your employment in accordance with the Company’s standard payroll policies and will be subject to applicable tax
reporting and tax withholding. 
 Annual Performance Bonus: You will be eligible to receive an annual performance bonus up to thirty-five (35)
percent of annual base salary prorated for four-fifths (4/5) time based on achieving certain milestones which shall be mutually agreed to between the Board of Directors and you. 

Stock Option and Restricted Stock: You will be granted as incentive stock restricted shares totaling 10% of the Company’s common stock (1.87M
shares) subject to approval of, and at a price to be determined by the Company’s Board of Directors, which will be equal to the fair market value of our common stock on the date of grant. Your restricted shares, which will be subject to the
standard terms and conditions of ModeRNA Therapeutics, Inc.’s 2010 stock incentive plan, will be brought to the Board of Directors for approval soon after you begin employment with the Company. Following the approval by the Company’s Board
of Directors the shares will vest, subject to continued employment, over four years at a rate of 25% on the first anniversary of the commencement date of your employment and an additional 6.25% per quarter for the next twelve successive quarters of
employment. 
 Company Agreements: the offer of employment is contingent upon you signing ModeRNA Therapeutics Confidentiality, Intellectual Property
and Non-compete and Non-solicitation agreements. These agreements are attached to this offer letter. You will be required to submit documentation that establishes identity and employment eligibility in accordance with the US Immigration and
Naturalization requirements. The I-9 Employment Verification form is attached. 
 If there are any other agreements of any type that you are aware of which
may impact or limit your ability to perform your job at ModeRNA Therapeutics, please let us know as soon as possible. 

 You may indicate your acceptance of this offer by signing on the appropriate space below and returning a signed
copy along with the necessary agreements referenced in this letter in the enclosed stamped envelope to my attention. Your anticipated start date is April 1, 2011 but may be delayed to allow you to receive appropriate US immigration status. 

Stephane, we are all excited about the opportunity to work with you. Feel free to contact any of us if you have any questions or need more information. On
behalf of all our team members, let me extend a sincere welcome. 
  

	
	Sincerely,
	
	/s/ Noubar Afeyan
	 Noubar Afeyan
 Board Member

ModeRNA Therapeutics

  

	
	Accepted and Agreed to:
	
	/s/ Stephane Bancel
	Stephane Bancel

 Date 
 2/24/2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]